First-Ever Creator Token Skyrockets to 100x - $DON, Launched by XCAD Network on Gate.io and MEXC, Delivers Stellar Performance on Day One
May 10, 2024 01:18 ET
|
XCAD/Xacademy
Dubai, May 10, 2024 (GLOBE NEWSWIRE) -- XCAD Network, a leading Watch2Earn tokenisation platform for YouTubers, has achieved significant success with its first-ever full product creator token $DON,...
"Fast Start Close More" Sales Training Bootcamp: Revolutionizing Financial Advisory Success
May 09, 2024 20:47 ET
|
Producers Prospect
Scottsdale, May 09, 2024 (GLOBE NEWSWIRE) -- Scottsdale, Arizona - Producers Prospect, in partnership with the acclaimed Taylor Method, is thrilled to announce the "Fast Start Close More" Sales...
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
May 09, 2024 16:30 ET
|
Travere Therapeutics, Inc.
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 ...
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:10 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Phunware Reports Significant Improvement in First Quarter 2024 Financial Results
May 09, 2024 16:05 ET
|
Phunware, Inc.
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Phunware, Inc. (NASDAQ: PHUN) (“Phunware” or the “Company”), the leading provider of patented wayfinding and mobile engagement solutions that enables...
Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance
May 09, 2024 16:05 ET
|
Elutia Inc.
SILVER SPRING, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a company pioneering drug-eluting biomatrix products, today provided a business update...
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
May 09, 2024 16:05 ET
|
4D Molecular Therapeutics, Inc.
Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3...
IBEX Announces Third Quarter of Fiscal Year 2024 Financial Results with Record Performance
May 09, 2024 16:05 ET
|
Ibex Limited
WASHINGTON, May 09, 2024 (GLOBE NEWSWIRE) -- IBEX Limited (“ibex”), a leading provider in global business process outsourcing and end-to-end customer engagement technology solutions, today announced...
CarGurus Announces First Quarter 2024 Results
May 09, 2024 16:01 ET
|
CarGurus, Inc.
1Q’24 Marketplace Revenue and QARSD growth accelerated further to 12% YoY and 14% YoY, respectively 1Q’24 Consolidated Net Income of $21.3 million, up 80% YoY; 1Q’24 Non-GAAP Adjusted EBITDA of $50.4...
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase...